目前全人源TRAIL受体( TRAIL-Rs)的单克隆抗体(单抗)对肿瘤靶向治疗已进入临床Ⅰ~Ⅳ期研究。 TRAIL-Rs单抗可分别与死亡受体TRAIL-R1和TRAIL-R2结合,形成死亡诱导信号复合体( DISC),诱导肿瘤细胞凋亡,成为抗肿瘤抗体药物研发的热点之一。全人源TRAIL-Rs单抗与放疗、化疗药物或其它制剂以及免疫治疗方法联合应用在肿瘤治疗中取得了显著的效果,为临床抗肿瘤治疗提供了新方案。%Monoclonal antibodies(mAbs)to human TRAIL receptors(TRAIL-Rs)have been developed in tumor targeted therapy and currently used in clinical Ⅰ~Ⅳtrials.MAbs can bind death-receptors(TRAIL-R1 and TRAIL-R2)and then results in formation of the death inducing signaling complex (DISC)and apoptosis of tumor cells.TRAIL -Rs mAbs have become one of the research and development hotspots of anti -tumor drugs.These mAbs have achieved remarkable results in combination with radio -or chemo-therapy drugs or oth-er agents and immunotherapy in the treatment of tumor and offer a new therapeutic strategy for clinical tumor treatment.
展开▼